Drugs / tabelecleucel
tabelecleucel
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed post-transplant lymphoproliferative disease 2 milestones | |||||
| Filed | US (FDA) | — | post-transplant lymphoproliferative disease | 2026-09-30 | “its partner, Pierre Fabre Pharmaceuticals, Inc. (PFP), has resubmitted the tabelecleucel Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).” atarabio.com ↗ |
| Rejected (CRL) | US (FDA) | Ebvallo | post-transplant lymphoproliferative disease | 2026-01-09 | “the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the EBVALLO™ (tabelecleucel) Biologics License Application (BLA)” atarabio.com ↗ “submitted a briefing book to the FDA addressing the points from the Complete Response Letter dated January 9, 2026” atarabio.com ↗ “the Complete Response Letter (CRL) to the Biologics License Application (BLA) for tabelecleucel (tab-cel)” atarabio.com ↗ |
| Approved Indication not stated 7 milestones | |||||
| Filed | US (FDA) | EBVALLO | Epstein-Barr virus positive post-transplant lymphoproliferative disease | 2025-07-14 | “the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for tabelecleucel (tab-cel ® )” atarabio.com ↗ “resubmitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (EBVALLO™ or tab-cel ® )” atarabio.com ↗ |
| Clinical hold | US (FDA) | EBVALLO | Epstein-Barr virus positive post-transplant lymphoproliferative disease | 2025-01-21 | “U.S. FDA issues clinical hold on EBVALLO ™ (tabelecleucel) and ATA3219 studies linked to EBVALLO Complete Response Letter (CRL)” atarabio.com ↗ |
| Rejected (CRL) | US (FDA) | EBVALLO | Epstein-Barr virus positive post-transplant lymphoproliferative disease | 2025-01-16 | “today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the EBVALLO TM (tabelecleucel) Biologics License Application (BLA)” atarabio.com ↗ |
| Filed | US (FDA) | — | Epstein-Barr virus positive post-transplant lymphoproliferative disease | 2024-07-17 | “the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for tabelecleucel (tab-cel ® )” atarabio.com ↗ |
| Filed | US (FDA) | — | Epstein-Barr virus positive post-transplant lymphoproliferative disease | 2024-05-20 | “Atara has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (tab-cel ® )” atarabio.com ↗ |
| Approved | EU (EMA) | Ebvallo | — | 2022-12-16 | europa.eu ↗ |
| Filed | EU (EMA) | — | Epstein-Barr virus-positive post-transplant lymphoproliferative disease | 2021-11-30 | “the Marketing Authorization Application (MAA) for tabelecleucel (tab-cel ® ) has been fully validated by the European Medicines Agency (EMA).” atarabio.com ↗ |
Trials 8
News releases announcing trial results or a regulatory action · 45
| Date | Issuer | Release |
|---|---|---|
| 2026-05-07 | Atara Biotherapeutics | Regulatory Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel atarabio.com ↗
The FDA agreed that a single arm study using an appropriate historical control applicable to the trial population, conducted in a pre-specified manner, could serve as an adequate and well controlled study and provide safety and efficacy data in support of a future marketing application of tab-cel for the proposed indication. |
| 2026-03-12 | Atara Biotherapeutics | Regulatory Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel atarabio.com ↗ |
| 2026-03-03 | Atara Biotherapeutics | Regulatory Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel atarabio.com ↗
today announced that its partner Pierre Fabre Pharmaceuticals (PFP) has submitted a request to the FDA for a Type A meeting. |
| 2026-01-12 | Atara Biotherapeutics | Regulatory Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel) atarabio.com ↗
The CRL indicates that the FDA is unable to approve the EBVALLO™ BLA in its present form. |
| 2025-07-24 | Atara Biotherapeutics | Regulatory Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease atarabio.com ↗
The BLA has been granted Priority Review with a Class 2 Resubmission Prescription Drug User Fee Act (PDUFA) target action date of January 10, 2026. |
| 2025-07-14 | Atara Biotherapeutics | Regulatory Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®) atarabio.com ↗ |
| 2025-05-05 | Atara Biotherapeutics | Regulatory Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel) atarabio.com ↗ |
| 2025-01-21 | Atara Biotherapeutics | Regulatory Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219 atarabio.com ↗
U.S. FDA issues clinical hold on EBVALLO ™ (tabelecleucel) and ATA3219 studies linked to EBVALLO Complete Response Letter (CRL) |
| 2025-01-16 | Atara Biotherapeutics | Regulatory Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel) atarabio.com ↗
The CRL was solely related to observations as part of a standard pre-license inspection of a third-party manufacturing facility for EBVALLO. |
| 2024-07-17 | Atara Biotherapeutics | Regulatory Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease atarabio.com ↗ |
| 2024-05-20 | Atara Biotherapeutics | Regulatory Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA atarabio.com ↗ |
| 2024-01-31 | Atara Biotherapeutics | Results Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology atarabio.com ↗
First Phase 3 Results Published for an Allogeneic T-Cell Therapy |
| 2023-11-29 | Atara Biotherapeutics | Results Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023 atarabio.com ↗
Pooled Analysis Shows 77.8% Objective Response Rate (ORR) in 18 EBV+ CNS PTLD Patients, Including First Line PTLD Setting and Promising Long-Term Survival |
| 2023-09-19 | Atara Biotherapeutics | Regulatory Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability atarabio.com ↗
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported important progress related to the regulatory pathway for tabelecleucel (tab-cel ® ) in the U.S. |
| 2023-06-05 | Atara Biotherapeutics | Results Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023 atarabio.com ↗ |
| 2023-02-08 | Atara Biotherapeutics | Regulatory Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel) atarabio.com ↗
Pierre Fabre and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced the transfer of the European Commission (EC) marketing authorization (MA) for EBVALLO ™ (tabelecleucel) for patients with relapsed or refractory Epstein‑Barr virus positive post‑transplant lymphoproliferative disease (EBV+ PTLD) from Atara to Pierre Fabre. |
| 2022-12-19 | Atara Biotherapeutics | Regulatory Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD atarabio.com ↗ |
| 2022-12-12 | Atara Biotherapeutics | Results Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting atarabio.com ↗
Phase 3 ALLELE Study Shows 51.2% Objective Response Rate (ORR) in 43 EBV+ PTLD Patients |
| 2022-11-08 | Atara Biotherapeutics | Regulatory Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress atarabio.com ↗
Ebvallo TM Positioned to be the First Allogeneic T-Cell Therapy Ever Approved Following CHMP Positive Opinion |
| 2022-10-14 | Atara Biotherapeutics | Regulatory CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease atarabio.com ↗
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the European Commission (EC) approval of Ebvallo TM (tabelecleucel) |
| 2022-06-04 | Atara Biotherapeutics | Results Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress atarabio.com ↗
Overall Response Rate (ORR) of 60% Observed in Patients with Relapsed or Refractory (R/R) EBV+ PTLD Consistent with Previously Reported Studies |
| 2021-12-13 | Atara Biotherapeutics | Results Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting atarabio.com ↗
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced efficacy and safety results from its Phase 3 multicenter ALLELE study investigating tabelecleucel (tab-cel ® ) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) following solid organ transplant (SOT) or hematopoietic cell transplant (HCT). |
| 2021-11-30 | Atara Biotherapeutics | Regulatory European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease atarabio.com ↗
today announced that the Marketing Authorization Application (MAA) for tabelecleucel (tab-cel ® ) has been fully validated by the European Medicines Agency (EMA). |
| 2021-11-04 | Atara Biotherapeutics | Results Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data atarabio.com ↗
Positive New ALLELE Results Show 50% Objective Response Rate (ORR) and Strong Safety Profile Reinforcing Transformative Potential of Tab-cel ® |
| 2021-09-27 | Atara Biotherapeutics | Regulatory European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD) atarabio.com ↗ |
| 2021-06-07 | Atara Biotherapeutics | Results Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect atarabio.com ↗
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced a combined long-term overall survival (OS) analysis from three clinical studies of tabelecleucel (tab-cel ® ) in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV + PTLD) after solid organ transplantation (SOT). |
| 2021-03-14 | Atara Biotherapeutics | Results Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting atarabio.com ↗
Combined analysis from these investigator-assessed studies demonstrates patients with EBV + PTLD after HCT that is relapsed or refractory (R/R) to rituximab who achieved either complete or partial response (CR or PR) after treatment with tab-cel ® derived similar OS benefit. |
| 2021-02-08 | Atara Biotherapeutics | Results Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience atarabio.com ↗
Results further illustrated that the tab-cel ® manufacturing process results in complementary clonal expansion and consistent enrichment of TCRs associated with productive engagement of EBV-driven diseases. |
| 2020-09-14 | Atara Biotherapeutics | Results Atara Biotherapeutics To Present Clinical Data in Epstein-Barr Virus-Driven (EBV+) Acquired & Primary Immunodeficiency Lymphoproliferative Diseases (AID-LPD and PID-LPD) from Tab-Cel® Expanded Access Program in e-Poster at ESMO 2020 Virtual Congress atarabio.com ↗
These data demonstrate that tab-cel ® was well-tolerated and showed encouraging clinical activity in patients with EBV + AID-LPD and PID-LPD. |
| 2019-12-09 | Atara Biotherapeutics | Results Atara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel® Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting atarabio.com ↗
Tab-cel ® was generally well-tolerated in all patients with EBV+ PTLD and other EBV-associated diseases. |
| 2019-11-06 | Atara Biotherapeutics | Results Atara Biotherapeutics to Present Tab-cel® Long-Term Clinical Outcomes from a Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting atarabio.com ↗
I am pleased with the tab-cel ® long-term clinical outcomes for patients with EBV+ PTLD we continue to observe in our EAP study,” said Pascal Touchon, President and Chief Executive Officer of Atara Biotherapeutics. |
| 2019-06-01 | Atara Biotherapeutics | Results Atara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting atarabio.com ↗
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today presented results showing that circulating EBV-targeted cytotoxic T lymphocyte precursors (EBV-CTLp) could serve as a biomarker of clinical response to tab-cel ® (tabelecleucel) in patients with EBV-driven diseases. |
| 2018-12-15 | Atara Biotherapeutics | Results Atara Biotherapeutics Presents Positive Efficacy and Safety Results for Patients with Epstein-Barr Virus-Associated Leiomyosarcoma (EBV+ LMS) atarabio.com ↗ |
| 2018-12-03 | Atara Biotherapeutics | Results Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual Meeting atarabio.com ↗
Another important study presents positive Phase 2 clinical results in patients with EBV+ PTLD involving the CNS. |
| 2018-06-15 | Atara Biotherapeutics | Results Atara Biotherapeutics’ Tab-cel™ Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas atarabio.com ↗
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced positive long-term outcomes including durable remissions and encouraging safety findings from two Phase 2 studies of tab-cel™ (tabelecleucel), Atara’s most advanced off-the-shelf T-cell immunotherapy. |
| 2018-05-17 | Atara Biotherapeutics | Results Atara Biotherapeutics to Present Long-Term Tab-cel™ Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas at 23rd Congress of European Hematology Association atarabio.com ↗
Results to be presented at the EHA meeting demonstrate the median survival for tab-cel™ treated patients with EBV+ PTLD following hematopoietic cell transplant (HCT) who failed rituximab was not reached after 23.3 months of follow-up. |
| 2017-12-29 | Atara Biotherapeutics | Regulatory Atara Biotherapeutics Announces FDA Clearance to Initiate Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) atarabio.com ↗
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies with tabelecleucel (formerly known as ATA129) in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD). |
| 2017-12-11 | Atara Biotherapeutics | Results Atara Biotherapeutics Announces Updated Positive Interim Results from Multicenter Expanded Access Study of tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus (EBV) Associated Post-Transplant Lymphoproliferative Disorder (PTLD) atarabio.com ↗
today announced that the Company's collaborating investigators presented updated, positive interim results for tabelecleucel (formerly known as ATA129) from a multicenter expanded access protocol (EAP) study for patients with EBV associated cancers. |
| 2016-10-18 | Atara Biotherapeutics | Regulatory Atara Bio Granted Access to Priority Medicines (PRIME) Regulatory Support for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL) for Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD) atarabio.com ↗
have granted access to the EMA’s newly established Priority Medicines (PRIME) regulatory initiative for EBV-CTL in the treatment of patients with rituximab refractory EBV-PTLD following hematopoietic cell transplant (HCT). |
| 2016-06-23 | Atara Biotherapeutics | Regulatory Atara Bio Receives Advanced Therapy Medicinal Product Classification for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) from European Medicines Agency (EMA) atarabio.com ↗
We are pleased to receive EMA’s classification of our EBV-CTL product candidate as an ATMP in the European Union. |
| 2016-06-06 | Atara Biotherapeutics | Results Atara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate atarabio.com ↗ |
| 2016-04-19 | Atara Biotherapeutics | Results Atara Bio’s Collaborator QIMR Berghofer Medical Research Institute Reports Positive Clinical Data for T Cell Immunotherapy in Nasopharyngeal Cancer (NPC), a Solid Tumor atarabio.com ↗
According to clinical results reported at the AACR meeting, 20 recurrent/metastatic NPC patients who received autologous targeted EBV-CTLs showed a median overall survival since the time of recruitment of 479 days. |
| 2016-03-23 | Atara Biotherapeutics | Regulatory Atara Bio Receives EMA Orphan Drug Designation for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder atarabio.com ↗
today announced that the European Medicines Agency (EMA) granted orphan drug designation for the Company’s allogeneic Epstein-Barr Virus targeted cytotoxic T-lymphocyte (EBV-CTL) product candidate for the treatment of patients with EBV Post-Transplant Lymphoproliferative Disorder (EBV-PTLD). |
| 2016-02-08 | Atara Biotherapeutics | Regulatory Atara Bio Receives FDA Orphan Drug Designation for EBV-CTL to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder (EBV-PTLD) atarabio.com ↗ |
| 2015-03-02 | Atara Biotherapeutics | Regulatory FDA Grants Breakthrough Therapy Designation to Epstein-Barr Virus (EBV) Targeted T-Cells for Treatment of EBV-Associated Lymphoproliferative Disease atarabio.com ↗
We are very pleased that our collaboration partner, MSK, has received breakthrough therapy designation, and we look forward to continuing our collective work to further develop this promising approach. |
All press releases naming this drug 55 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tabelecleucel | “receive IV infusion of tabelecleucel 2 × 10\^6 T-cells/kg” NCT01498484 ↗5“tabelecleucel (tab-cel®, ATA129), allogeneic EBV-CTLs” NCT00002663 ↗ |
| Known as | CNA12+ EBV CTL | “An equal dose (10x7/m2) of CNA12+ EBV CTL and CNA8+ EBV CTL will be administered intravenously on day 0.” NCT03131934 ↗ |
| Known as | CNA8+ EBV CTL | “An equal dose (10x7/m2) of CNA12+ EBV CTL and CNA8+ EBV CTL will be administered intravenously on day 0.” NCT03131934 ↗ |
| Known as | EBV-CTL | “Epstein-Barr virus-specific cytotoxic T lymphocyte (EBV-CTL) is an autologous adoptive T-cell immunotherapy generated from the blood of individuals and manufactured without...” PMID 39241963 ↗ Sep 2024 |
| Known as | Epstein-Barr virus-specific cytotoxic T lymphocyte | “Epstein-Barr virus-specific cytotoxic T lymphocyte (EBV-CTL) is an autologous adoptive T-cell immunotherapy generated from the blood of individuals and manufactured without...” PMID 39241963 ↗ Sep 2024 |
| Known as | tabelecleucel (tab-cel, ATA129), allogeneic EBV-CTLs | “tabelecleucel (tab-cel®, ATA129), allogeneic EBV-CTLs” NCT00002663 ↗ |
| Action | Deplete | “EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated...” NCT00002663 ↗ |
| Modality | Cell therapy | “Adoptive transfer of donor-derived EBV-specific cytotoxic T-lymphocytes (EBV-CTLs)” PMID 31689242 ↗ Feb 2020 |
| Route | Intravenous | “will receive IV infusion of tabelecleucel (tab-cel)” NCT00002663 ↗ |